There is no single best medication for multiple sclerosis. The right choice depends on how active your disease is, how it’s progressing, your tolerance for risk, and personal factors like whether you’re planning a pregnancy. That said, the treatment landscape has shifted dramatically: more than 20 disease-modifying therapies are now approved, and growing evidence favors starting with stronger medications earlier rather than working up to them over time.
How MS Medications Are Grouped
All MS disease-modifying therapies work by calming or redirecting the immune system to reduce attacks on the protective coating around nerve fibers. But they vary widely in how aggressively they do this, how they’re taken, and what side effects they carry. The practical way to think about them is in three tiers: modest efficacy, moderate efficacy, and high efficacy.
Modest-efficacy drugs include the injectable interferons and glatiramer acetate. These were the first MS treatments available and have decades of safety data behind them. They reduce relapse rates by roughly 30%, which is meaningful but modest compared to newer options. Moderate-efficacy oral medications like teriflunomide and dimethyl fumarate offer more convenience (a daily pill instead of injections) with similar or slightly better effectiveness. High-efficacy therapies, including ocrelizumab, ofatumumab, natalizumab, cladribine, and alemtuzumab, can cut relapse rates by 50% to 70% or more and are increasingly used as first-line treatments for people with active disease.
High-Efficacy Therapies Are Gaining Ground
For years, the standard approach was to start with a milder drug and escalate only if the disease broke through. That thinking is changing. European treatment guidelines now recommend considering a more efficacious drug for anyone on interferons or glatiramer acetate who shows signs of ongoing disease activity. Many neurologists now skip the escalation approach entirely and start with a high-efficacy therapy, especially for younger patients or those with frequent relapses or active lesions on MRI.
The logic is straightforward: nerve damage from MS is irreversible, so preventing it early matters more than treating it later. High-efficacy drugs do carry greater risks, but for many patients the math favors aggressive treatment upfront.
B-Cell Therapies: Ocrelizumab and Ofatumumab
Two of the most widely prescribed high-efficacy options target a specific type of immune cell called B cells. Ocrelizumab is given as an intravenous infusion every six months. Ofatumumab is a self-administered injection given monthly at home after an initial loading period. Both are highly effective at suppressing relapses and new MRI lesions.
A simulated treatment comparison published in 2022 found that ofatumumab showed a 40% lower annualized relapse rate than ocrelizumab when researchers compared data across their respective clinical trials. Ofatumumab also showed more favorable results for a composite measure called NEDA-3, which tracks relapses, disability progression, and MRI activity together. That said, head-to-head trials between the two haven’t been conducted, so these comparisons carry some uncertainty. In practice, the choice often comes down to whether you prefer infusion visits at a clinic or self-injecting at home.
Natalizumab: Highly Effective With a Specific Risk
Natalizumab remains one of the most potent MS therapies available. It works by blocking immune cells from crossing into the brain and spinal cord. The catch is a rare but serious brain infection called progressive multifocal leukoencephalopathy, or PML, caused by a common virus called JC virus.
Your risk depends on whether you carry antibodies to the JC virus and, if so, at what level. Patients who test negative for JC virus antibodies face minimal risk. Among those who test positive and have never taken other immune-suppressing drugs, the risk is about 1 in 1,000 per year. An antibody index below 0.9 signals minimal risk, while levels above 1.5 signal increased risk. Your neurologist will monitor these levels regularly. For JC virus-negative patients, natalizumab offers an exceptional benefit-to-risk ratio. For those who are positive with rising antibody levels, switching to another high-efficacy drug is common practice.
Oral Options and How They Compare
If you prefer a pill over injections or infusions, several oral therapies are available. They span the efficacy spectrum from moderate to high.
Dimethyl fumarate and teriflunomide are the most established moderate-efficacy oral drugs. A Swedish registry study found they differ in why patients stop taking them. Nearly half of all dimethyl fumarate discontinuations were due to side effects, primarily flushing and gastrointestinal symptoms like stomach pain and diarrhea. Patients on dimethyl fumarate were about 1.4 times more likely to quit due to side effects than those on teriflunomide. On the other hand, 45% of teriflunomide discontinuations were due to the drug simply not working well enough. So dimethyl fumarate tends to be more effective but harder to tolerate, while teriflunomide is easier on the body but may not suppress disease activity as strongly.
A class of oral drugs called S1P receptor modulators, which includes fingolimod, ozanimod, ponesimod, and siponimod, works by trapping certain immune cells inside lymph nodes so they can’t reach the brain. These cells normally follow a chemical gradient to exit the lymph nodes, but S1P modulators block that signal. The result is a significant drop in circulating immune cells that would otherwise attack nerve tissue. These drugs require cardiac monitoring when you start them because they can temporarily slow heart rate.
Cladribine sits in its own category. It’s a high-efficacy oral therapy with an unusual dosing schedule: you take tablets for a few days in two short cycles per year, for two years total, then stop treatment entirely for the following two years. In its pivotal trial, cladribine reduced the annualized relapse rate by 58% compared to placebo. This “treat and step away” approach appeals to people who don’t want to commit to continuous medication, though it requires waiting at least six months after the last dose before attempting conception.
Treatment for Progressive MS
Most approved therapies target relapsing forms of MS. Options for progressive disease are more limited but do exist. Ocrelizumab is approved for primary progressive MS, making it the first drug to receive that indication. Siponimod is approved for secondary progressive MS (the stage where relapsing disease transitions into steady worsening). In its clinical trial, siponimod reduced the risk of confirmed disability progression at three months by 21%. However, further analysis by the FDA suggested this benefit was primarily driven by its anti-inflammatory effect on the relapsing component of the disease rather than the underlying degenerative process. In practical terms, siponimod works best for secondary progressive MS that still has some inflammatory activity.
Pregnancy and Family Planning
If you’re considering pregnancy, your medication choice matters significantly. Only two disease-modifying therapies are currently considered safe to continue during pregnancy: interferon and glatiramer acetate. Both can be used at their usual doses throughout pregnancy.
Several drugs are clearly off-limits. Teriflunomide is classified as pregnancy category X due to its potential to cause birth defects. Fingolimod has been linked to increased rates of congenital anomalies and should be stopped at least two months before conception. Cladribine requires a six-month washout for both women and men before attempting conception. Alemtuzumab requires effective contraception for four months after each treatment cycle.
Natalizumab occupies a middle ground. Studies haven’t shown a higher risk of fetal malformations compared to the general population, so it can be used during pregnancy when the benefits outweigh the risks, particularly in women with highly active disease who might relapse severely without treatment. Ofatumumab and dimethyl fumarate currently lack enough evidence to be considered safe during pregnancy and should be stopped before or upon confirmation of conception.
How the Choice Is Actually Made
European and international guidelines frame the decision around four factors: your disease severity and activity level, your other health conditions, the drug’s safety profile, and drug accessibility. In practice, the conversation with your neurologist often starts with how active your MS is. Someone diagnosed after a single mild episode with few MRI lesions might reasonably start with a moderate-efficacy oral therapy. Someone with frequent relapses, many lesions, or early signs of disability accumulation is increasingly likely to be offered a high-efficacy therapy from the start.
Your lifestyle matters too. Some people are comfortable with twice-yearly infusions and prefer not to think about treatment in between. Others want the independence of a monthly self-injection or a daily pill. Some want to minimize long-term immune suppression and find cladribine’s short treatment course appealing. And if pregnancy is anywhere on the horizon, that narrows the field considerably. The “best” medication is the one that matches your disease activity, fits your life, and carries risks you understand and accept.